ITOS Pengajuan SEC - iTeos Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1808865

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to iTeos Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	EX-3.2	AMENDED AND RESTATED BYLAWS ITEOS THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of iTeos Therapeutics, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Section 1.2 Ot
August 29, 2025	EX-2.2	CONTINGENT VALUE RIGHTS AGREEMENT EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Sol
August 29, 2025	EX-99.(D)(6)	CONTINGENT VALUE RIGHTS AGREEMENT Exhibit (d)(6) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc.
August 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 iTeos Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissio
August 29, 2025	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ITEOS THERAPEUTICS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. I. The name of this corporation is iTeos Therapeutics, Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered agent of th
August 29, 2025	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ITEOS THERAPEUTICS, INC. (Name of Subject Company ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) T
August 29, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No.1) iTeos Therapeutics, Inc. (Name of Subject Comp SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No.1) iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46
August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	POS AM	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 29, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.
August 15, 2025	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ITEOS THERAPEUTICS, INC. (Name of Subject Company ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) TA
August 15, 2025	EX-99.(D)(1)	AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC. ITEOS THERAPEUTICS, INC. Exhibit (d)(1) Execution Version AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC.
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
August 1, 2025	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-T (Form Type) ITEOS THERAPEUTICS, INC. (Name of Subject Company – Issuer) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2) Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) ITEOS THERAPEUTICS, INC.
August 1, 2025	EX-99.(D)(3)	Limited Guaranty, dated as of July 18, 2025 (incorporated by reference to Exhibit (d)(3) to the Schedule TO). Exhibit (d)(3) LIMITED GUARANTY This Limited Guaranty, dated as of July 18, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of iTeos Therapeutics, Inc.
August 1, 2025	EX-99.(E)(12)	Form of Amended and Restated Certificate of Incorporation of the Company to be effective at the Effective Time. EX-99.(e)(12) Exhibit (e)(12) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. I. The name of this corporation is iTeos Therapeutics, Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be Corporation Service Center, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered a
August 1, 2025	EX-99.(A)(1)(D)	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(D) to the Schedule TO). Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC.
August 1, 2025	EX-99.(D)(2)	Mutual Confidentiality Agreement, dated June 10, 2025, by and between iTeos and Tang Capital Management, LLC (incorporated by reference to Exhibit (d)(2) to the Schedule TO). Exhibit (d)(2) AGREEMENT FOR DISCLOSURE OF CONFIDENTIAL INFORMATION FROM ITEOS THERAPEUTICS INC.
August 1, 2025	SC 14D9	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therap SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 1, 2025	EX-99.(A)(1)(C)	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated herein by reference to Exhibit (a)(1)(C) to the Schedule TO). Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC.
August 1, 2025	EX-99.(A)(1)(B)	Form of Letter of Transmittal (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO). Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of ITEOS THERAPEUTICS, INC.
August 1, 2025	EX-99.(E)(13)	Form of Amended and Restated Bylaws of the Company to be effective at the Effective Time. EX-99.(e)(13) Exhibit (e)(13) AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of iTeos Therapeutics, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Sec
August 1, 2025	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) TANG CAPITAL PARTNER
August 1, 2025	EX-99.(A)(1)(A)	Offer to Purchase, dated August 1, 2025 (incorporated by reference to Exhibit (a)(1)(A) to the Schedule TO). TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC.
July 22, 2025	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therap SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Numb
July 21, 2025	EX-2.1	Agreement and Plan of Merger, dated as of July 18, 2025, by and among iTeos Therapeutics, Inc., Concentra Biosciences, LLC, and Concentra Merger Sub VIII, Inc. Execution Version AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC.
July 21, 2025	EX-10.1	Form of Contingent Value Rights Agreement by and between Concentra Biosciences, LLC, Concentra Merger Sub VIII, Inc., and a wholly owned Subsidiary of Concentra Biosciences, LLC. Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•] (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), [•], as Rights Agent (as defined herein),
July 21, 2025	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclo UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
July 21, 2025	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therap SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Numb
July 21, 2025	EX-99.1	iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.
June 17, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
June 5, 2025	DEFA14A	FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
June 5, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
May 28, 2025	EX-10.2	First Amendment to the Employment Agreement between iTeos Therapeutics, Inc. and Matthew Call, dated May 27, 2025 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND MATT CALL This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and Matt Call (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of the closing o
May 28, 2025	EX-10.3	First Amendment to the Employment Agreement between iTeos Therapeutics, Inc. and David Feltquate, dated May 27, 2025 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND DAVID FELTQUATE This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and David Feltquate (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of J
May 28, 2025	8-K	FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission F
May 28, 2025	EX-10.1	First Amendment to the Employment Agreement between iTeos Therapeutics, Inc. and Michel Detheux, dated May 27, 2025 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND MICHEL DETHEUX This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and Michel Detheux (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of the
May 28, 2025	EX-99.1	iTeos Therapeutics Announces Its Intention to Wind Down Operations - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales includi iTeos Therapeutics Announces Its Intention to Wind Down Operations - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass.
May 13, 2025	EX-99.1	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival - Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program - iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass.
May 13, 2025	8-K	Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission F
April 28, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
April 24, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents ev UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 5, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc.
March 5, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 ITEOS THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the amended and restated policy of iTeos Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (the “In
March 5, 2025	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware
March 5, 2025	S-8	As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No.
March 5, 2025	EX-10.15	Employment Agreement between the Company and David Feltquate (incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form 10-K (File No. 001-39401), filed with the SEC on March 5, 2025). Exhibit 10.15 David Feltquate [***] July 18, 2024 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and David Feltquate (the “Executive”) and is effective as of July 31, 2024 (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and condit
March 5, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
January 13, 2025	EX-99.1	Advancing Science.Designing Hope. JPM HC Conference January 2025 Advancing Science. Designing Hope. JPM HC Conference January 2025 Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are in
November 21, 2024	SC 13G	ITOS / iTeos Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment SC 13G 1 sc13g07422itos11212024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title
November 21, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g07422itos112124.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 21, 2024 with respect to the Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on b
November 18, 2024	EX-4	Joint Filing Agreement, dated November 18, 2024, among Mr. Davis and BCM. CUSIP No. 46565G104 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree that
November 18, 2024	EX-4	Joint Filing Agreement, dated November 18, 2024, among Mr. Davis and BCM. EX-4 2 ff4136206ex4-iteos.htm CUSIP No. 46565G104 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutic
November 18, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff413620613da6-iteos.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (
November 18, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) Josh La Grange Fried,
November 14, 2024	SC 13G/A	ITOS / iTeos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 itos13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ITeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
November 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
October 15, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / Boxer Asset Management Inc. Activist Investment SC 13D/A 1 ff399106113da5-iteos.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (
October 15, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff399714013da-iteosboxcap.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G
September 30, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree to the filing of
September 30, 2024	SC 13G	ITOS / iTeos Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
September 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commis
September 16, 2024	EX-99.2	Cancer Immunotherapiesby design™ GALAXIES Lung-201 Update ESMO 2024 Cancer Immunotherapies by design™ GALAXIES Lung-201 Update ESMO 2024 Forward-Looking Statements This presentation contains forward-looking statements.
September 16, 2024	EX-99.1	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - Clinically mean iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - Clinically meaningful objective response rate (ORR) of 63.
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
May 14, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) Josh La Grange Fried,
May 14, 2024	SC 13D/A	ITOS / iTeos Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2414521d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA
May 13, 2024	EX-4.1	Form of Exchange Warrant. EX-4.1 Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN
May 13, 2024	EX-4.2	Form of Pre-Funded Warrant. EX-4.2 Exhibit 4.2 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: May 14, 2024 iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”),
May 13, 2024	EX-99.1	SECURITIES PURCHASE AGREEMENT EX-99.1 Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 10, 2024, by and among iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, including its successors and assigns, an “Investor” and together, the “Investors”). WHEREAS, the Company des
May 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 iTeos Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission F
May 10, 2024	424B5	iTeos Therapeutics, Inc. 1,142,857 Shares of Common Stock Pre-Funded Warrant to Purchase up to 5,714,285 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271793 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) iTeos Therapeutics, Inc. 1,142,857 Shares of Common Stock Pre-Funded Warrant to Purchase up to 5,714,285 Shares of Common Stock We are offering directly to Boxer Capital, LLC (“Boxer Capital”) 1,142,857 shares of our common stock, par value $0.001 per share (the “
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 6, 2024	EX-97.1	iTeos Therapeutics Inc. Policy for Recoupment of Incentive Compensation Exhibit 97.1 ITEOS THERAPEUTICS, INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of iTeos Therapeutics, Inc. (the “Company”) has adopted a policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based
March 6, 2024	S-8	As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No.
March 6, 2024	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc.
March 6, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu
March 6, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware
February 16, 2024	SC 13G	ITOS / iTeos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G 1 iteostherapeutics13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ITeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) February 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the
February 14, 2024	SC 13G/A	ITOS / iTeos Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga207422itos02142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par
February 13, 2024	SC 13G/A	ITOS / iTeos Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01232-iteostherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: iTeos Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 46565G104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to
January 10, 2024	EX-99.1	EX-99.1 Cancer Immunotherapies by design ™ Nasdaq: ITOS January 2024iteostherapeutics.com Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar ex
January 10, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
January 10, 2024	EX-99.1	Cancer Immunotherapiesby design™ Nasdaq: ITOS January 2024 Cancer Immunotherapies by design™ Nasdaq: ITOS January 2024 Forward-Looking Statements This presentation contains forward-looking statements.
January 9, 2024	SC 13G/A	ITOS / iTeos Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ITOSSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ITEOS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appro
December 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
October 24, 2023	SC 13G	ITOS / ITeos Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ITOSSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ITEOS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Number) OCTOBER 17, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate
August 8, 2023	EX-10.1	Consulting Agreement between the Registrant and Detlev Biniszkiewicz effective as of June 13, 2023 Exhibit 10.1 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: June 13, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Detlev Biniszkiewicz (“You” or “Consultant”) CONSULTANT’S ADDRESS: [***] (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Consultancy Letter Agree
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
August 8, 2023	EX-10.2	Consulting Agreement between the Registrant and Joanne Jenkins Lager effective as of July 21, 2023 Exhibit 10.2 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: July 21, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Dr. Joanne Jenkins Lager (“You” or “Consultant”) CONSULTANT’S ADDRESS: [***] (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Dear Dr. Lager, This
June 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
May 19, 2023	424B3	$125,000,000 Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) Filed Pursuant to Rule 424(b)(3) Registration No.
May 17, 2023	CORRESP	iteostherapeutics.com United States Belgium 321 Arsenal Street Rue des Freres Wright Bldg 312, Suite 301 6041 Gosselies, Belgium Watertown, MA 02472-5710 May 17, 2023 VIA EDGAR U.
May 10, 2023	S-3	As filed with the Securities and Exchange Commission on May 10, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2023 Registration No.
May 10, 2023	EX-1.2	Sales Agreement, dated as of May 10, 2023, by and between the Registrant and Cowen and Company, LLC Exhibit 1.2 ITEOS THERAPEUTICS, INC. UP TO $125,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENT May 10, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company a
May 10, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) iTeos Therapeutics, Inc.
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 15, 2023	EX-10	Addendum to Employment Contract between iTeos Belgium S.A. and Yvonne McGrath dated September 23, 2020 Exhibit 10.18 Informal translation from the original French ADDENDUM TO THE EMPLOYMENT CONTRACT BETWEEN The company iTeos Belgium SA Whose registered office is located at Rue des Frères Wright 29 6041 Gosselies – Belgium Company number: 0838.316.659 here represented by Michel Detheux in his capacity as CEO and President hereinafter referred to as the “Employer” or the “Company” AND Mrs Yvonne McGr
March 15, 2023	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc.
March 15, 2023	S-8	As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.
March 15, 2023	EX-21	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware
March 15, 2023	EX-10	Amendment No. 2 to Collaboration and License Agreement between iTeos Belgium S.A and GlaxoSmithKline Intellectual Property (No. 4) Limited dated September 30, 2022 (incorporated by reference to Exhibit 10.15 of the Registrant’s Annual Report on Form 10-K (File 001-39401) filed on March 15, 2023). Exhibit 10.15 Execution Copy Amendment No. 2 to Collaboration and LICENSE AGREEMENT This Amendment No. 2 (“Amendment No. 2”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) and previously amended on January 24, 2022, between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having busin
March 15, 2023	EX-10	Amendment No. 1 to Collaboration and License Agreement between iTeos Belgium S.A and GlaxoSmithKline Intellectual Property (No. 4) Limited dated January 24, 2022 (incorporated by reference to Exhibit 10.14 of the Registrant’s Annual Report on Form 10-K (File 001-39401) filed on March 15, 2023). Exhibit 10.14 Execution Version Amendment No. 1 to Collaboration and LICENSE AGREEMENT This Amendment No. 1 (“Amendment No. 1”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brent
March 15, 2023	EX-10	Consultancy Letter Agreement between iTeos Therapeutics, Inc. and Matthew Roden effective as of January 31, 2023 image health Exhibit 10.22 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: January 31, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Matthew Roden (“You” or “Consultant”) CONSULTANT’S ADDRESS: (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Consultancy Letter A
March 15, 2023	EX-10	Letter Agreement between iTeos Therapeutics, Inc. and Yvonne McGrath dated November 23, 2022 (incorporated by reference to Exhibit 10.19 of the Registrant’s Annual Report on Form 10-K (File 001-39401) filed on March 15, 2023). Exhibit 10.19 321 Arsenal Street Bldg. 312, Suite 301 Watertown, MA 02472-5710 United States Informal translation from the original French Yvonne McGrath [***] Gosselies, Belgium November 23, 2022 Dear Mrs. Yvonne McGrath, Concerns: iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan This letter concerns the potential grant and/or any given grant to Yvonne McGrath (the “Optionee”) of sto
March 15, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
February 14, 2023	SC 13G/A	ITOS / iTeos Therapeutics Inc / RTW INVESTMENTS, LP - ITEOS THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0696sc13ga.htm ITEOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement
February 14, 2023	SC 13G/A	ITOS / iTeos Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number)
February 9, 2023	SC 13G	ITOS / iTeos Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01193-iteostherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: iTeos Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 46565G104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule purs
February 3, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
January 9, 2023	EX-99.1	Better Immunotherapiesto Improve the Lives of People with Cancer Nasdaq: ITOS January 2023 Better Immunotherapies to Improve the Lives of People with Cancer Nasdaq: ITOS January 2023 Forward-Looking Statements This presentation contains forward-looking statements.
January 9, 2023	EX-99.1	EX-99.1 iteostherapeutics.com Better Immunotherapies to Improve the Lives of People with Canceriteostherapeutics.com Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
November 10, 2022	EX-10.1	First Amendment to the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q (File No. 001-39401) filed on November 10, 2022). Exhibit 10.1 FIRST AMENDMENT TO THE ITEOS THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN Pursuant to Section 18 of the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the ?Plan?), the Plan is hereby amended as follows: The definition of ?Compensation? in Section 11 of the Plan is hereby deleted and replaced in its entirety with the following: ?The term ?Compensation? means the am
August 12, 2022	CORRESP	As of Dec. 31, 2021 iTeos Therapeutics, Inc. 321 Arsenal Street, Building 3, Suite 301 Watertown, MA 02472 www.iTeosTherapeutics.com VIA EDGAR August 12, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Li Xiao and Mary Mast Re: iTeos Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 23, 2022 File N
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
June 13, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2022 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
June 13, 2022	EX-99.1	ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as amended (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of iTeos Therapeutics, Inc. (the ?Company?)
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
May 11, 2022	SC 13D/A	ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.
May 2, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 2, 2022 with respect to the Common Stock, $0.001 par value per share of iTeos Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with th
May 2, 2022	SC 13G	ITOS / iTeos Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
April 25, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 25, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
March 23, 2022	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware
March 23, 2022	EX-10.14	Lease Agreement between ARE-MA Region No. 75, LLC and iTeos Therapeutics, Inc. dated November 8, 2021 (incorporated by reference to Exhibit 10.14 of the Registrant's Annual Report on Form 10-K (File No. 001-39401) filed on March 23, 2022). Exhibit 10.14 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 8 day of November, 2021, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ITEOS THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: The specific building in the Project located at 321 Arsenal Street, Watertown, Massachusetts 02472 (also known as Building 312),
March 23, 2022	EX-10.15	Employment Contract between iTeos Belgium S.A. and Yvonne McGrath effective as of May 18, 2020 (incorporated by reference to Exhibit 10.15 of the Registrant's Annual Report on Form 10-K (File No. 001-39401) filed on March 23, 2022). Exhibit 10.15 Translated from the original French EMPLOYMENT CONTRACT BETWEEN The company iTeos Belgium SA Having its registered address at Rue des Freres Wright 29 3041 Gosselies ? Belgium Company number: 0838.316.659 Represented by Philippe Brantegem In his capacity as Vice-President Human Resources Hereafter referred to as ? the Employer ? or ? the Company ? AND Mrs. Yvonne McGrath Residing at
March 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu
March 23, 2022	S-8	As filed with the Securities and Exchange Commission on March 23, 2022 As filed with the Securities and Exchange Commission on March 23, 2022 Registration No.
March 23, 2022	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc.
March 21, 2022	SC 13D/A	ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2022	SC 13G/A	ITOS / iTeos Therapeutics Inc / RTW INVESTMENTS, LP - ITEOS THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
January 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
January 11, 2022	EX-99.1	Targeted Immunotherapies to Improve the Lives of People with Cancer January 2022 Nasdaq: ITOS Targeted Immunotherapies to Improve the Lives of People with Cancer January 2022 Nasdaq: ITOS Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws.
January 6, 2022	SC 13D/A	ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.
December 10, 2021	SC 13D/A	ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person
December 10, 2021	EX-99.C	Joint Filing Statement Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc.
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
October 19, 2021	EX-99.C	Joint Filing Statement Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc.
October 19, 2021	SC 13D/A	ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person
September 21, 2021	EX-99.C	Joint Filing Statement Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc.
September 21, 2021	SC 13D/A	ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person
August 11, 2021	EX-10.1	Collaboration and License Agreement between iTeos Belgium S.A and GlaxoSmithKline Intellectual Property (No. 4) Limited dated June 11, 2021 (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39401) filed on August 11, 2021). Exhibit 10.1 Certain information (indicated by ?[*]?) and schedules have been excluded from this agreement because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT Between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED And ITEOS belgium s.a. Table of Contents Article 1 Definitions 1 Article 2 Effectiv
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
August 10, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissio
July 28, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
June 16, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission
June 14, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
May 13, 2021	EX-10.1	Third Amended and Restated Collaboration Agreement between iTeos Belgium SA and Adimab, LLC, dated February 22, 2021 (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39401) filed on May 13, 2021). Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDED AND RESTATED COLLABORATION AGREEMENT This Third Amended and Restated Collaboration Agreement (the ?Agreement?) is
May 13, 2021	EX-99.1	iTeos Reports First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports First Quarter 2021 Financial Results and Provides Business Update - Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 - - Inupadenant updated monotherapy clinical data and evidence of association of A2A receptor expression with anti-tumor act
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
May 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission F
May 5, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 5, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
May 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 (April 29, 2021) ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporatio
May 4, 2021	EX-99.1	iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors Exhibit 99.1 iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors Cambridge, MA and Gosselies, Belgium ? May 3, 2021 ? iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for pat
April 12, 2021	EX-99.1	iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 Exhibit 99.1 iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 ? Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed ? EOS-448 showed prelimina
April 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 (April 10, 2021) ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorpora
April 12, 2021	EX-99.2	Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. F Immunotherapies to Improve and Extend the Lives of People with Cancer EOS-448 update - April 12th, 2021 Exhibit 99.
March 24, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
March 24, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 24, 2021 Registration No.
March 24, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu
March 24, 2021	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts
March 24, 2021	EX-4.3	Description of Securities Exhibit 4.3 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The common stock, par value $0.001 per share (?Common Stock?), of iTeos Therapeutics, Inc. (?iTeos,? ?we,? or ?our?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description sets forth certain general terms and p
March 24, 2021	EX-99.1	iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12th to discuss results – - Updated, single-agent data of inupadenant (EOS-850) from Phase 1/2a trial and initial pe
March 22, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission
February 4, 2021	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of iTeos Therapeutics, Inc.
February 4, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __N/A__)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 11, 2021	EX-99.1	Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. F EX-99.1 Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021 Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Lit
January 11, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Comm
November 12, 2020	EX-99.1	iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update - Patient enrollment in Phase 1/2 studies of EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continues with initial data expected in 1H21 - - Strong cash position to support ongoing clinical development and operations into 2023 - Cambridge, MA and Gosselies, Belgium – November 12, 2020
November 12, 2020	EX-99.2	iTeos Appoints Matthew Roden, Ph.D. to Board of Directors Exhibit 99.2 iTeos Appoints Matthew Roden, Ph.D. to Board of Directors Cambridge, MA and Gosselies, Belgium – November 12, 2020 - iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Matthew Roden, Ph.D.,
November 12, 2020	EX-99.3	Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. F Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression November 2020 Exhibit 99.
November 12, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
September 1, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss
September 1, 2020	EX-99.1	iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update - July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 - - EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continue to progress in clinical trials- Cambridge, MA and Gosselies, Belgium – September 1, 2020 - iTeos Therapeutics, Inc. (Nasdaq: ITOS), a
September 1, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc.
August 10, 2020	SC 13D	ITOS / iTeos Therapeutics, Inc. / MPM BioVentures 2014, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of P
August 10, 2020	EX-99.C	Joint Filing Statement EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. is filed on behalf of each of the undersigned. Date: August 7, 2020 MPM BIOVENTURES 2014, L.P. By: MPM BioVentures 2014 GP LLC, its General Pa
August 7, 2020	SC 13D	ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.
August 7, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree that this Joint Filing Agreement
August 5, 2020	SC 13D	ITOS / iTeos Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) RA Ca
July 28, 2020	EX-3.3	Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-39401) filed with the Securities and Exchange Commission on July 28, 2020) EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla
July 28, 2020	EX-3.2	Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39401) filed with the Securities and Exchange Commission on July 28, 2020) EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. iTeos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is iTeos Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secreta
July 28, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on July 28, 2020 Registration No.
July 28, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commiss
July 27, 2020	424B4	PROSPECTUS 10,586,316 Shares 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-239415 PROSPECTUS 10,586,316 Shares Common stock This is an initial public offering of shares of common stock by iTeos Therapeutics, Inc. We are offering 10,586,316 shares of our common stock. The initial public offering price is $19.00 per share. Prior to this offering, there has been no public market for our shares. Ou
July 23, 2020	S-1MEF	- S-1MEF S-1MEF As filed with the Securities and Exchange Commission on July 23, 2020. Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 84-3365066 (State or other jurisdiction of incorporation or organizat
July 21, 2020	CORRESP	- CORRESP July 21, 2020 United States Securities and Exchange Commission 100 F Street, N.
July 21, 2020	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3365066 (State of incorporation or organization) (I.R.S. Employer Identification No.) 139 Main Str
July 21, 2020	CORRESP	- CORRESP VIA EDGAR July 21, 2020 Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.
July 20, 2020	EX-10.8	Form of Director Indemnification Agreement EX-10.8 Exhibit 10.8 ITEOS THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve th
July 20, 2020	EX-10.12	Employment Agreement between the Registrant and Matthew Gall (Incorporated by reference to Exhibit 10.12 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed with the Securities and Exchange Commission on July 20, 2020) EX-10.12 Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Matthew Gall (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Da
July 20, 2020	EX-3.4	Form of Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-239415)). EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla
July 20, 2020	CORRESP	- CORRESP July 20, 2020 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.
July 20, 2020	EX-10.10	Employment Agreement between the Company and Matthew Call (incorporated by reference to Exhibit 10.10 of the Company’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020). EX-10.10 Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Matt Call (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”
July 20, 2020	EX-10.9	Employment Agreement between the Company and Michel Detheux, Ph.D. (incorporated by reference to Exhibit 10.9 of the Company’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020). EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Michel Detheux (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Da
July 20, 2020	EX-10.4	Master Services Agreement between iTeos Belgium and WuXi Biologics (Hong Kong) Limited, dated March 21, 2017 (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020). EX-10.4 Exhibit 10.4 CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. BIOLOGICS MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is dated March 22, 2
July 20, 2020	EX-10.7	Form of Indemnification Agreement, by and between the Company and its officers (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1/A (File No. 333-239415), filed with the SEC on July 20, 2020). EX-10.7 Exhibit 10.7 ITEOS THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the
July 20, 2020	EX-4.2	Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed with the Securities and Exchange Commission on July 20, 2020) EX-4.2 Exhibit 4.2 ZQ\|CERT#\|COY\|CLS\|RGSTRY\|ACCT#\|TRANSTYPE\|RUN#\|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.001 Certificate Shares Number * * 000000 ****************** * * * 000000 *************** ZQ00000000 000000 ************ ITEOS THERAPEUTICS, INC. * 000000 *********** ** 000000 ********** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Mr. Alexander David
July 20, 2020	S-1/A	- S-1/A S-1/A Table of Contents As filed with Securities and Exchange Commission on July 20, 2020 Registration No.
July 20, 2020	EX-10.5	2020 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.5 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-239415)). EX-10.5 Exhibit 10.5 ITEOS THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of iTeos Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (
July 20, 2020	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 J.P. MORGAN SECURITIES LLC ITEOS THERAPEUTICS, INC. [•] Shares of Common Stock Underwriting Agreement July [●], 2020 J.P. Morgan Securities LLC SVB Leerink LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC One Federal Street, 37th Floor
July 20, 2020	EX-10.2	2020 Stock Option and Incentive Plan, and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-239415)). EX-10.2 Exhibit 10.2 ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of iTeos Therapeutics, Inc. (the “Company”) an
July 20, 2020	EX-10.13	Form of Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement EX-10.13 Exhibit 10.13 Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement In consideration and as a condition of my employment by between iTeos Therapeutics, Inc. (including its subsidiaries and other affiliates and its and their successors and assigns, the “Company”) and in exchange for, among other things, my eligibility for certain severance benefits provided in
July 20, 2020	EX-10.11	Employment Agreement between the Registrant and Joanne Jenkins Lager, M.D. (Incorporated by reference to Exhibit 10.11 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed with the Securities and Exchange Commission on July 20, 2020) EX-10.11 Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Joanne Jenkins Lager, (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Eff
July 20, 2020	EX-10.6	Senior Executive Cash Incentive Bonus Plan EX-10.6 Exhibit 10.6 ITEOS THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of iTeos Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals an
July 20, 2020	EX-3.2	Form of Second Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-239415)). EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. iTeos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is iTeos Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secreta
June 24, 2020	EX-10.3	Second Amended and Restated Collaboration Agreement between iTeos Belgium SA and Adimab, LLC, dated July 23, 2018 EX-10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT THIS SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agre
June 24, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ITEOS THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law). DOES HEREBY CERTIFY: 1.
June 24, 2020	EX-10.1	2019 Stock Option and Grant Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020). EX-10.1 Exhibit 10.1 ITEOS THERAPEUTICS, INC. 2019 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2019 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of iTeos Therapeutics, Inc., a Delaware corporat
June 24, 2020	EX-4.1	Amended and Restated Stockholders’ Agreement, dated as of March 24, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020). EX-4.1 Exhibit 4.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT THIS AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”), is mad
June 24, 2020	S-1	Power of Attorney S-1 Table of Contents As filed with Securities and Exchange Commission on June 24, 2020 Registration No.
June 24, 2020	EX-3.3	By-laws of the Registrant, as currently in effect EX-3.3 Exhibit 3.3 BY-LAWS of ITEOS THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors; provided, however, that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held
June 24, 2020	CORRESP	- CORRESP June 24, 2020 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.
June 24, 2020	EX-21.1	Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium
May 22, 2020	EX-3.3	BY-LAWS ITEOS THERAPEUTICS, INC. (the “Corporation”) EX-3.3 Exhibit 3.3 BY-LAWS of ITEOS THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors; provided, however, that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held
May 22, 2020	DRS	- DRS Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on May 22, 2020.
May 22, 2020	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ITEOS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ITEOS THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law). DOES HEREBY CERTIFY: 1.

ITOS / iTeos Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)